Orenitram and Humalog drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Orenitram (treprostinil) and Humalog (insulin lispro recombinant). Common drug interactions include cough among females and headache among males.

The phase IV clinical study analyzes what interactions people have when they take Orenitram and Humalog. It is created by eHealthMe based on reports of 56 people who take the same drugs from the FDA, and is updated regularly.

What is Orenitram?

Orenitram has active ingredients of treprostinil. eHealthMe is studying from 17,714 Orenitram users. Check the latest studies of Orenitram.

What is Humalog?

Humalog has active ingredients of insulin lispro recombinant. It is often used in diabetes. eHealthMe is studying from 137,127 Humalog users. Check the latest studies of Humalog.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.



On Sep, 01, 2026

56 people who take Orenitram and Humalog together, and have interactions are studied.

Orenitram and Humalog drug interactions.

What are the common drug interactions of Orenitram and Humalog, by gender? *:

female:

  1. Cough
  2. Device failure
  3. Drug ineffective
  4. Frequent bowel movements
  5. Gait disturbance
  6. Injection site haemorrhage (bleeding from injection site)
  7. Mucosal haemorrhage (bleeding from mucous membrane)
  8. Night sweats (sweating in night)
  9. Pancreatic disorder
  10. Peritonitis (inflammation of the peritoneum, the thin tissue that lines the inner wall of the abdomen and covers most of the abdominal organs)

male:

  1. Headache (pain in head)
  2. Head discomfort
  3. Blood pressure increased
  4. Cardiac failure
  5. Confusional state
  6. Diarrhoea
  7. Dyspnoea exertional (breathlessness or shortness of breath)
  8. Fatigue (feeling of tiredness)
  9. Flushing (the warm, red condition of human skin)
  10. Hospitalisation

What are the common drug interactions of Orenitram and Humalog, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

  1. Impaired gastric emptying
  2. Nausea (feeling of having an urge to vomit)
  3. Vomiting
  4. Abdominal pain
  5. Cholelithiasis (the presence or formation of gallstones in the gallbladder or bile ducts)
  6. Device related infection

50-59:

  1. Headache (pain in head)
  2. Diarrhoea
  3. Malaise (a feeling of general discomfort or uneasiness)
  4. Nausea (feeling of having an urge to vomit)
  5. Retching (strong involuntary effort to vomit)
  6. Abdominal pain
  7. Cholelithiasis (the presence or formation of gallstones in the gallbladder or bile ducts)
  8. Device related infection
  9. Dyspnoea (difficult or laboured respiration)
  10. Hemiparesis (weakness on one side of the body)

60+:

  1. Nausea (feeling of having an urge to vomit)
  2. Pneumonia
  3. Vomiting
  4. Respiratory failure (inadequate gas exchange by the respiratory system)
  5. Blood pressure decreased
  6. Cardiac failure congestive
  7. Cardio-respiratory arrest (sudden dysfunction of heart and lungs)
  8. Sinus node dysfunction (a group of abnormal heart rhythms)
  9. Syncope (loss of consciousness with an inability to maintain postural tone)
  10. Fall

What are the existing conditions these people have? *

  1. Primary Pulmonary Hypertension (primary high blood pressure that affects the arteries in the lungs and the right side of your heart): 47 people, 83.93%
  2. Nausea (feeling of having an urge to vomit): 6 people, 10.71%
  3. High Blood Pressure: 5 people, 8.93%
  4. Neuropathy Peripheral (surface nerve damage): 4 people, 7.14%
  5. Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 4 people, 7.14%
  6. High Blood Cholesterol: 4 people, 7.14%
  7. Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 4 people, 7.14%
  8. Cardiac Failure: 4 people, 7.14%
  9. Sleep Disorder: 3 people, 5.36%
  10. Pulmonary Hypertension (increase in blood pressure in the lung artery): 3 people, 5.36%

* Approximation only. Some reports may have incomplete information.

Do you take Orenitram and Humalog?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Orenitram and Humalog:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Orenitram:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Humalog:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Orenitram and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Humalog and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on treprostinil and insulin lispro recombinant (the active ingredients of Orenitram and Humalog, respectively), and Orenitram and Humalog (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: